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AbsTrACT
background advances in stent-assisted coiling have 
incrementally expanded endovascular treatment options 
for complex cerebral aneurysms. after successful coil 
consolidation and aneurysm occlusion, endovascular 
scaffolds are no longer needed. Thus, bioresorbable 
stents that disappear after aneurysm healing could avoid 
future risks of in-stent thrombosis and the need for 
lifelong antiplatelet therapy.
Objective To assess the applicability and compatibility 
of a bioresorbable magnesium- alloy stent (brMas) for 
assisted coiling.
Methods saccular sidewall aneurysms were created 
in 84 male Wistar rats and treated with brMas alone, 
brMas + aspirin, or brMas + coils + aspirin. control 
groups included no treatment (natural course), 
solely aspirin treatment, or conventional cobalt–
chromium stent + coils + aspirin treatment. after 1 
and 4 weeks, aneurysm specimens were harvested 
and macroscopically, histologically, and molecularly 
examined for healing, parent artery perfusion status, 
and inflammatory reactions. stent degradation was 
monitored for up to 6 months with micro-computed and 
optical coherence tomography.
results aneurysms treated with brMas showed 
advanced healing, neointima formation, and subsequent 
stent degradation. additional administration of aspirin 
sustained aneurysm healing while reducing stent-induced 
intraluminal and periadventitial inflammatory responses. 
no negative interaction was detected between platinum 
coils and brMas. Progressive brMas degradation was 
confirmed.
Conclusions brMas induced appropriate healing in 
this sidewall aneurysm model. The concept of using 
bioresorbable materials to promote complete aneurysm 
healing and subsequent stent degradation seems 
promising. These results should encourage further device 
refinements and clinical evaluation of this treatment 
strategy for cerebrovascular aneurysms.
bACkgrOuND
Endovascular coiling techniques for intracranial 
aneurysms have continuously improved since their 
introduction in the 1990s.1 However, consider-
able aneurysm reperfusion rates (up to 30%) and 
inapplicability for wide-necked aneurysms remain 
significant limitations of conventional coiling.2–4 
Stent-assisted coiling helped to overcome some 
of these challenges. First introduced in 1997, this 
technique combined a balloon-mounted coronary 
stainless steel stent with Guglielmi detachable coils.5 
The stent acts as a bridging scaffold over the aneu-
rysm neck and prevents coil migration. It simulta-
neously allows higher coil packing and provides an 
endoluminal matrix for endothelial growth, which 
ultimately decreases aneurysm reperfusion rates.6 
A major disadvantage of stent implantation is the 
increased risks of local thrombus formation and 
ischemic stroke that necessitate lifelong antiplatelet 
therapy. This may lead to side effects without 
completely eliminating the risks of late stent throm-
bosis and in-stent stenosis.7 Permanent stents may 
also cause an intraparenchymal foreign-body reac-
tion,8 9 which, along with the implanted inert coils, 
can impede complete aneurysm healing. The endo-
vascular scaffold becomes unnecessary after coil 
integration and aneurysm healing. Devices that 
resorb after coil-induced thrombus organization 
and complete aneurysm occlusion could obviate the 
risks associated with a lasting stent. Recent advances 
in material science have enabled the development of 
bioresorbable vascular implants composed of poly-
L-lactic acid and a magnesium alloy.10 Bioresorb-
able stent use has already been studied in clinical 
trials for stenotic coronary artery disease.11 12 Our 
study aimed to investigate the impact of a biore-
sorbable magnesium-alloy stent (brMAS) on early 
aneurysm remodelling in a rat sidewall saccular 
aneurysm model.
MeThODs
study design
Decellularized sidewall saccular aneurysms were 
created in 84 male Wistar rats that underwent 
subsequent treatments: brMAS alone (n=23), 
brMAS +aspirin (n=19), brMAS + coils + aspirin 
(n=7), aspirin alone (n=6), conventional cobalt–
chromium stent (CoCrS) + coils + aspirin (n=6), 
and no treatment (n=23). Aneurysm healing, perfu-
sion status of the underlying vessel, and inflamma-
tory reactions were examined and compared among 
the six groups. Magnesium-alloy stent degradation 
was tracked monthly for 6 months (figure 1).
Animals
Animals were aged ≥12 weeks, weighed 567±73 g, 
and received care in accordance with institutional 
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guidelines. Experiments were approved by the Committee for 
Animal Care of the Canton Bern, Switzerland (BE 65/16). In 
accordance with ARRIVE (Animal Research: Reporting of In 
Vivo Experiments) guidelines,13 an a priori power analysis was 
performed to calculate sample sizes for experimental subgroups.
Aneurysm formation and stent placement
After anesthesia induction by inhalation of isoflurane 4%, an 
intraperitoneal injection of 0.5 mg/kg medetomidine (Medetor, 
Virbac, Switzerland) and 50 mg/kg ketamine hydrochloride 
(Ketalar, Pfizer, Switzerland) was administered. As previously 
described, sidewall aneurysms were created by end-to-side anas-
tomosis of an arterial vessel pouch from a donor animal (thoracic 
aorta) to the clamped abdominal aorta of a recipient animal. 
All grafts had previously been decellularized by incubation in 
0.1% sodium dodecyl sulfate for 10 hours at 37°C.14 A digital 
video camera (Sony NEX-5R, Sony, Tokyo, Japan) attached 
to a stereo microscope (OPMI, Carl Zeiss AG, Oberkochen, 
Germany) was used to document aneurysm dimensions preop-
eratively, at harvest, and during operative procedures. With 
aneurysm formation, the abdominal aorta was cannulated below 
the iliolumbar artery, and the stent was introduced through an 
intravasal lock and dilatator using a modified Seldinger tech-
nique.15 The two devices were a magnesium-alloy stent coated 
with degradable poly-L-lactic acid polymer (Biotronik, Bülach, 
Switzerland), 6 mm length (2.5 mm diameter), and nominal pres-
sure of 8 bar; and a conventional CoCrS (Pro-Kinetic Energy, 
Biotronik), 9 mm length (2.5 mm diameter), and nominal pres-
sure of 9 bar. A target helical ultra-coil (Stryker, Kalamazoo, 
Michigan, USA) of 2 cm length (2 mm diameter) was used for 
coiling. Aspirin (Alcacyl 500, Hänseler AG, Switzerland) was 
administered weight-adapted via restriction of these animals to 
aspirin-enriched drinking water (2000 mg/L).
Fluorescence angiography, macroscopic inspection, and tissue 
preparation
A laparotomy was performed for aneurysm dissection at the spec-
ified follow-up time. Fluorescence angiography was performed 
to assess dynamic perfusion status after intravenous injection of 
2 mL fluorescein (fluorescein 10% Faure, 0.5 g/5 mL), followed 
by illumination (light source 465 to 490 nm) of the aneu-
rysm, which was filmed with a specified detection filter as previ-
ously described.16 After animals were euthanized by overdosing 
with intracardial ketamine hydrochloride (Narketan, 120 mg/
kg ketamine injection, Vetoquinol, Switzerland), the aneurysm 
was harvested and measured in all dimensions, and the poste-
rior aorta was opened to inspect the aneurysm orifice. Tissues 
were immediately shock frozen on dry ice for molecular anal-
ysis or fixed in formalin (4% weight/volume solution, J.T. Baker, 
Arnhem, The Netherlands) until embedded in paraffin for histo-
logical analysis.
Post mortem analysis
Gelatine sodium dodecyl sulfate-polyacrylamide gel electropho-
resis zymography was performed to detect the enzymatic activity 
of matrix metalloproteinase (MMP)-2 and -9. Protein homog-
enates (5 µg) were submitted to electrophoresis under non-re-
ducing conditions in polyacrylamide gels containing type A 
gelatine from porcine skin (1% v/v). The assessment of cytokines/
chemokines or other analytes was performed using a rat magnetic 
Luminex assay 7-Plex kit (R&D Systems, Minneapolis, Minne-
sota, USA), according to the manufacturer instructions. Concen-
trations of the different analytes were determined in 100 µg of 
crude protein homogenates using Bio-Plex Manager Software 
4.1.1 (Bio-Rad Laboratories, Hercules, California, USA) with 
a 5-parameter logistic curve-fitting method. The histological 
study included hematoxylin-eosin, Masson-Goldner trichrome, 
smooth muscle actin, and von Willebrand factor (F8) staining. 
Further post mortem analyses included optical coherence tomog-
raphy (OCT) and micro-computed tomography (μCT) imaging 
of the aneurysm and underlying vessels. A detailed description of 
the methods is given in the online supplementary data.
statistical analysis
Statistical analysis was performed with Graph Pad Prism 7 
(version 7.02, GraphPad software, San Diego, California, USA). 
Linear regression analysis was used to compare healing status 
(complete vs residual perfusion). Numeric samples of two groups 
Figure 1 Study flowchart showing the numbers of animals in each experimental condition. Exclusions from the final analysis were deaths caused 
by subacute hemorrhage (n=4), anesthesia-related problems (n=1), acute in-stent thrombosis (n=1), failure of stent deconvolution (n=1), pulmonary 
embolism (n=1), and unknown (n=3). Exclusions due to morbidity necessitating premature euthanasia were anesthesia-related problems (n=3), 
subacute in-stent thrombosis (n=2), intestinal perforation (n=1), and unknown (n=1). ASA, aspirin; brMAS, bioresorbable magnesium-alloy stent; 
CoCrS, permanent cobalt–chromium stent; µCT, micro-CT; OCT, optical coherence tomography.
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were compared with Mann-Whitney U tests for non-paramet-
rically distributed values and Student t-tests for parametrically 
distributed values. One-way analyses of variance followed by 
Dunn’s multiple comparison tests were used to study heteroge-
neity in multiple groups. Values are expressed as median and 
IQR or mean±SD. A p value <0.05 was considered statistically 
significant.
resulTs
brMAs highlights
Aneurysms treated with brMAS showed pronounced healing, 
strong neointima formation, and stent degradation. At the 
4-week follow-up, fluorescence angiography and macroscopic 
inspection showed complete aneurysm occlusion in 22 of 26 
brMAS stent-treated animals compared with 4 of 20 animals 
without stents (p<0.0001, figure 2). The endothelium-free 
aneurysm orifice showed a strong neointima after brMAS 
stenting, which prevented aneurysm perfusion. Histological and 
molecular analyses showed increased locoregional inflamma-
tion in stent-treated animals compared with untreated. Aspirin 
significantly reduced inflammation in stent-treated animals as 
observed in histological assessments and based on inflammatory 
protein expression. Qualitative μCT and OCT revealed progres-
sive degradation of brMAS; we observed fractures and clefts in 
the stent loop integrity and progressive rarefication of metal 
content in the vessel wall (figure 3).
Aneurysm remodeling and inflammatory response
Microscopic evaluation confirmed advanced healing with 
neointima formation but expectedly higher inflammation after 
brMAS treatment compared with no stent: significantly more 
neutrophils accumulated in the thrombi of aneurysms with 
stent treatment than in those without stents (p=0.028). Aspirin 
administration in animals with stents significantly reduced aneu-
rysm wall inflammation (p=0.02) and yielded better neointima 
formation (p=0.02), with no significant difference in inflamma-
tory cells in the thrombi. Online supplementary figure I shows 
the detailed histological analysis. The increased inflammatory 
reaction after stent placement was confirmed by quantitative 
molecular analyses. Luminex analysis of proinflammatory cyto-
kines (interleukin [IL]−6 and IL-1β) and gelatine zymography 
for matrix-degrading MMP-9 showed that concentrations were 
highest after 1 week of aneurysm treatment and decreased at 
week 4 (all values given in the online supplementary table). 
Aspirin administration effectively reduced levels of proinflam-
matory cytokines in stent-treated animals in the acute period 
(week 1) Concentrations of IL-1β (p=0.01), IL-6 (p=0.045), 
MMP-9 (p=0.009), and MMP-2 (p=0.01) were significantly 
lower after 1 week in brMAS + aspirin treated animals compared 
with brMAS treatment without aspirin. In the chronic phase of 
aneurysm healing (week 4), there were no significant differ-
ences in inflammation marker levels in the brMAS + aspirin and 
untreated groups.
stent-assisted coiling with brMAs
No macroscopic or histological signs of negative interactions 
were detected between the platinum coils and brMAS, such as 
increased cellular reactions, material failure, or tissue necrosis. 
Furthermore, there were no differences in aneurysm healing 
between coiled aneurysms with brMAS or CoCrS (example of 
histology shown in figure 4, analysis in online supplementary 
figure II). Except for one CoCrS-treated case, all aneurysms 
treated by brMAS or CoCrS + coils showed complete healing 
with coherent neointima formation and no residual perfu-
sion after 4 weeks. No differences were observed between the 
two stent groups for periadventitial inflammation (p>0.99), 
aneurysm wall inflammation (p>0.99), or neutrophils in the 
thrombus (p>0.99).
Mid-term and long-term findings and stent degradation
Preserved aneurysm healing with no residual perfusion was 
observed at monthly follow-up examinations from 1 to 6 
months. Complete stent endothelialization was achieved, and the 
mean neointima thickness varied from 137.26 µm at 1 month, 
75.33 µm at 2 months, 66.99 µm at 3 months, 97.87 µm at 4 
months, and 80.17 µm at 6 months, as assessed by OCT (see 
Figure 2 Comparison of a completely healed aneurysm after stent 
treatment and a poorly healed untreated aneurysm. Gross complete 
healing was noted after opening the parent artery opposite the 
aneurysm (A), and fluorescence angiography (B) confirmed a continuous 
neointima over the former orifice with no residual perfusion inside 
the aneurysm (*) after treatment with a bioresorbable magnesium 
alloy stent (arrows). Poor healing in macroscopic (C) and fluorescence 
angiographic (D) views of a 28-day-old untreated aneurysm.
Figure 3 Micro-CT (µCT) 3D reconstruction (upper row) and optical 
coherence tomography (OCT) reconstruction (lower row) showing 
progressive stent degradation after 1 month (A and D), 3 months (B 
and E), and 4 months (C and F) follow-up. µCT shows progressive loss 
of scaffold integrity (arrows). Degradation of magnesium (circles) is 
best seen on OCT because the laser is reflected on magnesium but 
penetrates temporary calcium phosphate deposits that resulted from 
stent degradation; this has a density similar to magnesium and can 
therefore not be distinguished on µCT.
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onlinesupplementary figure III). No systemic or in situ comor-
bidities or negative side effects of brMAS were detected on any 
follow-up examination. In particular, we did not detect intralu-
minal debris with progressive stent degradation. Qualitative μCT 
and OCT investigations showed progressive brMAS degradation 
characterized by fractures and clefts in the stent loop integrity 
and progressive rarefication of metal content in the vessel wall 
(figure 3).
DisCussiON
Our study aimed to evaluate the histopathological effects of a 
contemporary brMAS on early aneurysm remodeling to assess 
whether its material and design properties are suitable for further 
research efforts. Bioresorbable magnesium-alloy stents prompted 
adequate aneurysm healing responses in the rat model, and no 
negative interactions between platinum coils and brMAS were 
detected in the histological analysis.
Although brMAS is clinically approved for coronary artery 
disease, cerebrovascular applications are relatively new. To the 
best of our knowledge, only two studies have investigated the 
use of bioresorbable stents for aneurysm treatment. Extended 
analysis of interaction with thrombus formation, vessel wall 
remodeling, and data on combined use with coils are lacking. 
Using endovascular placement in a rabbit aneurysm model, 
Wang et al17 reported effective aneurysm occlusion in all 12 of 
the animals treated with magnesium-alloy stents. Similarly, Wang 
et al18 reported effective and safe treatment of carotid artery 
aneurysms in 13 rabbits using bioresorbable magnesium flow 
diverters. We confirmed good rates of aneurysm healing with 
brMAS treatment in our rat model.
In addition, our study provides new data for endothelium-free 
aneurysm orifice remodeling, inflammation processes, and 
stent–coil interactions. Besides the provided mechanical barrier 
for coils, stents promote neointimal proliferation and serve as 
scaffolds for cells that will eventually form a neointimal layer 
that changes hemodynamics and facilitates aneurysm occlu-
sion.19 This is important, because aneurysms with rarefication 
of mural cells are prone to growth and rupture.20 Owing to their 
decreased cellularity, these aneurysms exhibit reduced ability 
for aneurysm healing and neointima forming, as aneurysm-or-
ganizing cells are mainly recruited from the adjacent parent 
vessel.21 22 Accordingly, stent placement will help these cells to 
settle down along the scaffold, and, particularly, also along the 
aneurysm orifice.
Locoregional inflammation induced by intravascular implants 
is of concern as it may induce critical, rupture-prone alterations 
of the aneurysm wall, especially in cases where subsequent coil 
implantation might fail. On the other hand, inflammation at the 
injured endothelium and media layers is essential in aneurysm 
healing. It activates vascular smooth muscle cells to proliferate 
and phenotypically switch from contractile to synthetic cells 
that synthesize a matrix to support aneurysm cicatrization and 
neointima formation.23–25 However, an overwhelming inflam-
matory reaction may promote aneurysm formation, growth, 
and rupture.26 Pronounced inflammation after stent implan-
tation should therefore be controlled to promote adequate 
healing. We observed that aspirin significantly reduced inflam-
mation after stent implantation (particularly in the vulnerable 
first weeks), and aneurysm treatment with brMAS + coils and 
aspirin achieved fast aneurysm healing, strong neointima forma-
tion, aneurysmal scarification without residual perfusion, and 
subsequent stent degradation. Most clinically used stents are 
pharmaceutically coated with an immunosuppressant (ie, siro-
limus). We used stents without an immunosuppressive coating to 
reduce potential interference in our analysis of material–tissue 
interactions.
Lifelong antiplatelet medication is essential to avoid in-stent 
thrombosis and thromboembolic events. Tissues are particu-
larly vulnerable immediately after stent implantation. The early 
thrombosis rate may even be higher for current bioresorbable 
stents than with conventional metal stents; therefore, antiplatelet 
treatment remains essential in the acute phase.27 However, 
following neointima formation and aneurysmal scarification, the 
adverse effects of long-term aspirin use prevail.28 In an alterna-
tive approach to overcome drawbacks of systemic (dual) anti-
platelet therapy, a recent study suggested phosphorylcholine 
Figure 4 Representative histologic images of aneurysms treated with a cobalt–chromium stent (A) and bioresorbable magnesium-alloy stent (B) 
after 28 days. Treatment with either stent induced strong neointima formation with a thick cell layer over the former aneurysm orifice and advanced 
thrombus organization. *Coil artifact; †stent artifact.
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surface modification of flow diverters to reduce platelet-spe-
cific thrombogenicity.29 The rationale for using brMAS is that 
complete stent degradation would allow for complete cessation 
of an antiplatelet regimen.
Bioresorbable magnesium-alloy stents functioned well in combi-
nation with conventional uncoated platinum coils. As balloon 
inflation itself will induce some degree of endothelial damage and 
thus interfere with aneurysm remodeling activities, as a first step 
we chose to compare brMAS-induced endothelialization and aneu-
rysm healing processes with those following use of a contempo-
rary balloon-expandable CoCrS. In addition, CoCrSs are known 
for favorable endovascular biocompatibility versus other metal 
compositions.30 Notably, brMAS performed comparably to the 
latest generation of CoCrS. No relevant differences were observed 
in neointima formation, orifice obliteration, aneurysm healing, or 
inflammatory reaction. However, we did not formally assess the 
contribution of differences in stent design (eg, mesh forms, size, 
length) to the results. The relevance of scaffold design remains 
unclear, as a previous study which compared different flow-di-
verter designs in a rabbit aneurysm model reported temporal and 
spatial dependency of endothelialization on scaffold design, but no 
difference in final aneurysm occlusion.22
Whereas the first stent-assisted coiling treatments used 
balloon-expandable coronary stainless-steel stents, modern neuro-
vascular stents are commonly made of nitinol. Their superelastic 
and shape memory properties allow for self-expandable devices, 
facilitating gentle stent deployment, which reduces the risk of 
endothelial damage. Another favorable feature of contemporary 
neurovascular nitinol stents is their thin strut thickness (<100 µm). 
In stenotic coronary artery disease, increasing strut thickness 
correlates with the restenosis rate.31 Nitinol stents of the same 
strut thickness offer less radial force than cobalt–chromium, which 
is why nitinol stents are not widely used in coronary disease, 
where stents need to hold against stenotic atherosclerotic vessels.32 
Strength properties are less critical in assisted coiling; treatment 
is not directed towards an atherosclerotic vessel, which is why 
lowering strut thickness is appropriate. In contrast, current brMAS 
are produced using a weaving technique that affects the minimal 
achievable strut thickness (the brMAS strut thickness used was 
120 µm), making balloon expansion necessary.
While stent-treated aneurysms remained obliterated over 
the mid- and long-term follow-up, we confirmed continuous 
brMAS degradation over time. This is consistent with data from 
previous studies in a porcine heart model, which showed more 
than two-thirds degradation after 6 months, over 95% degrada-
tion after 1 year and nearly complete degradation (99.8%) after 
2 years of a stent that was 3 mm longer and sirolimus covered, 
but otherwise identical to the scaffold we used.33 34 The relatively 
rapid degradation of early magnesium stents represents a main 
limitation in atherosclerotic coronary arteries, where longer 
mechanical support is desirable. However, fast degradation 
may be advantageous in neurovascular indications, as coils need 
only short-term support until a neointima is formed. Further-
more, brMAS degradation rates are modifiable, depending on 
the alloy mixture, stent dimensions, and coverings of the stent.12 
During bioresorbable stent degradation, neointimal thickness 
may initially increase before reaching stable luminal dimen-
sions.17 35 Our series confirmed neointima remodeling during 
the first few months with a subsequent steady state of thickness 
after 5 months.
Although our preclinical findings show promising brMAS–
aneurysm interactions, specific stent adaptations and refinements 
are needed to meet the requirements for eventual clinical neuro-
vascular applications. Nevertheless, the field of bioresorbable 
endovascular materials is evolving and could create new treat-
ment strategies for cerebrovascular diseases.
limitations
Our investigation of brMAS for aneurysm therapy focused on 
the acute and early chronic phases but did not examine long-
term effects. No late in-stent stenosis occurred during the 
6-month study period. Other limitations are associated with the 
aneurysm model itself: surgical aneurysm creation substantially 
affects inflammation and healing. We minimized this by choosing 
appropriate follow-up time points. Furthermore, surgical aneu-
rysm creation and endovascular treatment were performed at 
the same time to reduce animal distress and increase survival. 
This setting did not allow for digital subtraction angiography; 
evaluation of the perfusion status of the aneurysm and under-
lying vessel was based on in-vivo fluorescence angiography and 
post mortem macroscopic and histologic evaluation. In addition, 
our study focused on the suitability of brMAS in aneurysmatic 
disease, and on compatibility of brMAS with coils. In a more 
advanced state, a bioresorbable stent specifically optimized for 
stent-assisted coiling should also be evaluated in the light of 
dual antiplatelet standard medication. Lastly, aneurysm creation 
was standardized across animals, but sutured aneurysms in rats 
obviously lack some properties of naturally formed cerebral 
aneurysms (eg, sidewall position, exposure to non-physiological 
blood flow, tissue environment). Better understanding of brMAS 
performance in cerebral aneurysms will be achieved by testing in 
a rabbit bifurcation model that exhibits similar flow dynamics to 
those of cerebral aneurysms and allows for angiographic imaging 
and distant endovascular stent deployment.
CONClusiON
In conclusion, brMAS treatment was feasible and successful in 
our rat sidewall model with adequate aneurysm remodeling. 
Pronounced inflammation triggered by the bioresorbable scaffold 
was markedly reduced by administration of aspirin. Using biore-
sorbable materials to enable complete healing with subsequent 
degradation of foreign materials is a promising concept that could 
be developed in the clinical setting of cerebrovascular disease.
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